Cotinga Pharmaceuticals (formerly Critical Outcome Technologies) is a biopharmaceutical company that specializes in the development of cancer treatments. It focuses on researching the survival and spreading mechanisms of cancer cells, primarily the small-molecule activators of misfolded mutant p53 proteins. The company also offers an AI-based platform that identifies compounds developing from disease-specific drug discovery.